Stocktoria

Elevance Health, Inc. ELV

NYSE · stock · Hospital & Medical Service Plans · website · IPO 2001-10-30 · LEI

Elevance Health, Inc. (ELV) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.78% (safety: safe). FY2025 revenue was $199.1B at a 2.8% net margin.

Chart by TradingView
63/100
Stocktoria Quality Score · grade B
6/9
Piotroski F — financial health
3.13
Altman Z″ — distress risk · safe
1.4%
Dividend yield 5y avg · safe · Dividend payout 27.0%

Quality score trend · recomputed for each fiscal year

Piotroski F /9
6 5 7 8 6 6 6 7 4 6 2016201720182019202020212022202320242025
Altman Z″
3.30 3.06 3.25 3.51 3.28 3.14 3.07 3.17 2.99 3.13 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$399.14 as of 2026-08-01 · +25.3% 1y
$292.75$399.1452-wk
Market cap USD$85.8B
P / E15.2×
Dividend yield 5y avg1.4%
Net margin 5y avg3.6%
Return on equity 5y avg15.1%
Beta0.69
Employees96,129

Analyst price target

$449.10 +12.5% vs last
consensus: buy · 21 analysts
target range $393.00 – $492.00 · median $457.00
3 strong buy · 12 buy · 7 hold
Recent analyst actions
DateFirmRating
2026-07-17Leerink PartnersMarket Perform (main)
2026-07-16RBC CapitalSector Perform (main)
2026-07-16Wells FargoOverweight (main)
2026-07-16GuggenheimBuy (main)
2026-07-16BarclaysOverweight (main)
2026-07-16BairdNeutral (main)

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Forward estimates · earnings calendar →

Forward EPS est.$29.63
Forward P / E13.5×
Next ex-dividend2026-09-10

Consensus analyst estimates and scheduled dates — forward-looking, may change.

Smart money · insiders, last 12 months

Insiders net sold -$826,625 on the open market · 3 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Finance, Insurance & Real Estate · percentile among 1129 companies

Piotroski Fstronger than 89%
Net marginstronger than 35%
Return on equitystronger than 78%
Revenue growthstronger than 69%

Percentile vs other Finance, Insurance & Real Estate companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 6/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.181
Retained earnings / assets0.291
EBIT / assets0.059
Equity / liabilities0.568

Sector peers · similar-size Finance, Insurance & Real Estate companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
ELVElevance Health, Inc.6/93.1315.2+12.5%
CNCCENTENE CORP4/90.38+19.4%
HUMHUMANA INC5/95.138.8+10.1%
CICigna Group7/91.412.6+11.2%
MOHMOLINA HEALTHCARE, INC.4/93.625.4+11.7%
OSCROscar Health, Inc.4/9-2.18+27.5%
ALHCAlignment Healthcare, Inc.5/9-0.35+46.1%

All Finance, Insurance & Real Estate companies →

About Elevance Health, Inc.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

FAQ

Is ELV financially healthy?

Elevance Health, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does ELV pay a dividend, and is it safe?

Yes. Elevance Health, Inc. pays a dividend yielding about 1.78% with a 27.0% payout ratio, rated “safe” for safety.

How profitable is ELV?

In FY2025, Elevance Health, Inc. had a net margin of 2.8% and a return on equity of 12.9%.

Is ELV overvalued or undervalued?

Elevance Health, Inc. trades at about 15.8× trailing earnings — near its 10-year norm (10-year range 13.7×–21.4×, median 17.3×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for ELV?

The average Wall-Street price target for Elevance Health, Inc. is $449.10, about 12.5% above the recent price, from 21 analysts (consensus: buy).

Is ELV a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on Elevance Health, Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 15.2×, a dividend yield of 1.78%. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.